Dr. Piperdi on the Stimuvax Vaccine in Lung Cancer

Bilal Piperdi, MD
Published: Wednesday, Nov 20, 2013

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discussed a trial looking at a vaccine in patients with lung cancer at the 8th Annual New York Lung Cancer Symposium®.

The vaccine, called Stimuvax, was compared with placebo as maintenance therapy following chemoradiation. The primary endpoint, overall survival, was not met in the intent-to-treat population.

In patients who received concurrent chemoradiation saw a 10-month survival benefit when treated with the vaccine. Piperdi says more research is planned in this space.

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discussed a trial looking at a vaccine in patients with lung cancer at the 8th Annual New York Lung Cancer Symposium®.

The vaccine, called Stimuvax, was compared with placebo as maintenance therapy following chemoradiation. The primary endpoint, overall survival, was not met in the intent-to-treat population.

In patients who received concurrent chemoradiation saw a 10-month survival benefit when treated with the vaccine. Piperdi says more research is planned in this space.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x